{"id":"https://openalex.org/W2892292741","doi":"https://doi.org/10.1200/jco.2017.35.15_suppl.e16016","title":"Real world treatment utilization and outcomes of patients with metastatic bladder cancer by cisplatin eligibility in U.S. community oncology practice.","display_name":"Real world treatment utilization and outcomes of patients with metastatic bladder cancer by cisplatin eligibility in U.S. community oncology practice.","publication_year":2017,"publication_date":"2017-05-20","ids":{"openalex":"https://openalex.org/W2892292741","doi":"https://doi.org/10.1200/jco.2017.35.15_suppl.e16016","mag":"2892292741"},"language":"en","primary_location":{"id":"doi:10.1200/jco.2017.35.15_suppl.e16016","doi":"https://doi.org/10.1200/jco.2017.35.15_suppl.e16016","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2017.35.15_suppl.e16016","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5035118741","display_name":"Kyle Flannery","orcid":"https://orcid.org/0000-0001-5857-5251","observed_orcids":["https://orcid.org/0000-0001-5857-5251"]},"institutions":[{"id":"https://openalex.org/I1285764155","display_name":"Merck & Co., Inc., Rahway, NJ, USA (United States)","ror":"https://ror.org/02891sr49","country_code":"US","type":"company","lineage":["https://openalex.org/I1285764155"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Kyle Flannery","raw_affiliation_strings":["Merck and Co., Inc., Kenilworth, NJ;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Merck and Co., Inc., Kenilworth, NJ;","institution_ids":["https://openalex.org/I1285764155"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5062847731","display_name":"Jenny Black-Shinn","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210151469","display_name":"The US Oncology Network","ror":"https://ror.org/05xc20j70","country_code":"US","type":"other","lineage":["https://openalex.org/I4210151469"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jenny Black-Shinn","raw_affiliation_strings":["McKesson Specialty Health/US Oncology Network, The Woodlands, TX;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"McKesson Specialty Health/US Oncology Network, The Woodlands, TX;","institution_ids":["https://openalex.org/I4210151469"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5042859469","display_name":"Marley Boyd","orcid":"https://orcid.org/0000-0003-1335-1267","observed_orcids":["https://orcid.org/0000-0003-1335-1267"]},"institutions":[{"id":"https://openalex.org/I4210151469","display_name":"The US Oncology Network","ror":"https://ror.org/05xc20j70","country_code":"US","type":"other","lineage":["https://openalex.org/I4210151469"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Marley Boyd","raw_affiliation_strings":["The US Oncology Network, McKesson Specialty Health, The Woodlands, TX;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"The US Oncology Network, McKesson Specialty Health, The Woodlands, TX;","institution_ids":["https://openalex.org/I4210151469"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5034005227","display_name":"Ashish M. Kamat","orcid":"https://orcid.org/0000-0003-3546-9928","observed_orcids":["https://orcid.org/0000-0003-3546-9928"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ashish M. Kamat","raw_affiliation_strings":["The University of Texas MD Anderson Cancer Center, Houston, TX;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"The University of Texas MD Anderson Cancer Center, Houston, TX;","institution_ids":["https://openalex.org/I1343551460"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":3,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":1,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"35","issue":"15_suppl","first_page":"e16016","last_page":"e16016"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10458","display_name":"Bladder and Urothelial Cancer Treatments","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2746","display_name":"Surgery"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10458","display_name":"Bladder and Urothelial Cancer Treatments","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2746","display_name":"Surgery"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12695","display_name":"Urinary and Genital Oncology Studies","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2746","display_name":"Surgery"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10307","display_name":"Head and Neck Cancer Studies","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2733","display_name":"Otorhinolaryngology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/metastatic-bladder-cancer","display_name":"metastatic bladder cancer","score":0.9990000128746033},{"id":"https://openalex.org/keywords/cisplatin-based-chemotherapy","display_name":"cisplatin-based chemotherapy","score":0.7089999914169312},{"id":"https://openalex.org/keywords/first-line-treatment","display_name":"first-line therapy","score":0.7839999794960022},{"id":"https://openalex.org/keywords/overall-survival","display_name":"overall survival","score":0.6610000133514404},{"id":"https://openalex.org/keywords/renal-function","display_name":"renal function","score":0.6169999837875366},{"id":"https://openalex.org/keywords/creatinine-clearance","display_name":"creatinine clearance","score":0.8519999980926514},{"id":"https://openalex.org/keywords/ecog-performance-status","display_name":"ECOG performance status","score":0.9679999947547913},{"id":"https://openalex.org/keywords/community-oncology-practice","display_name":"community oncology practice","score":0.7480000257492065},{"id":"https://openalex.org/keywords/real-world-outcomes","display_name":"real-world outcomes","score":0.6380000114440918},{"id":"https://openalex.org/keywords/gemcitabine","display_name":"gemcitabine","score":0.7450000047683716},{"id":"https://openalex.org/keywords/carboplatin","display_name":"carboplatin","score":0.9850000143051147},{"id":"https://openalex.org/keywords/paclitaxel","display_name":"paclitaxel","score":0.9670000076293945},{"id":"https://openalex.org/keywords/treatment-utilization","display_name":"treatment utilization","score":0.6129999756813049},{"id":"https://openalex.org/keywords/elderly-patients","display_name":"elderly patients","score":0.45100000500679016},{"id":"https://openalex.org/keywords/treatment-disparities","display_name":"treatment disparities","score":0.33399999141693115},{"id":"https://openalex.org/keywords/mckesson","display_name":"McKesson","score":0.4339999854564667}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9352209568023682},{"id":"https://openalex.org/C2780258809","wikidata":"https://www.wikidata.org/wiki/Q414143","display_name":"Gemcitabine","level":3,"score":0.6572475433349609},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.6114551424980164},{"id":"https://openalex.org/C2780352672","wikidata":"https://www.wikidata.org/wiki/Q504775","display_name":"Bladder cancer","level":3,"score":0.6022247076034546},{"id":"https://openalex.org/C2781451048","wikidata":"https://www.wikidata.org/wiki/Q415588","display_name":"Carboplatin","level":4,"score":0.5268327593803406},{"id":"https://openalex.org/C159641895","wikidata":"https://www.wikidata.org/wiki/Q108377937","display_name":"Renal function","level":2,"score":0.5214621424674988},{"id":"https://openalex.org/C2778239845","wikidata":"https://www.wikidata.org/wiki/Q412415","display_name":"Cisplatin","level":3,"score":0.4728013873100281},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.44267037510871887},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.40245771408081055},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.38009583950042725},{"id":"https://openalex.org/C126894567","wikidata":"https://www.wikidata.org/wiki/Q105650","display_name":"Urology","level":1,"score":0.3490123152732849}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1200/jco.2017.35.15_suppl.e16016","doi":"https://doi.org/10.1200/jco.2017.35.15_suppl.e16016","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2017.35.15_suppl.e16016","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":1.0}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W7133184904","https://openalex.org/W2046702136","https://openalex.org/W2560282005","https://openalex.org/W2933397876","https://openalex.org/W4376868671","https://openalex.org/W4415726238","https://openalex.org/W7166106105","https://openalex.org/W4392765732","https://openalex.org/W2991967897","https://openalex.org/W4414125911"],"abstract_inverted_index":{"e16016":[0],"Background:":[1],"Cisplatin(cis)-based":[2],"therapy":[3],"is":[4,206],"standard":[5],"first-line":[6],"(1L)":[7],"treatment":[8],"for":[9],"patients":[10],"(pts)":[11],"with":[12,61,74,224],"metastatic":[13],"bladder":[14],"cancer":[15],"(mBC).":[16],"Many":[17],"pts":[18,45,84,119,134,143,240,253,258],"are":[19],"cis-ineligible":[20,142,252],"mostly":[21],"due":[22],"to":[23],"reduced":[24],"renal":[25],"function":[26],"(creatinine":[27],"clearance":[28],"(CrCl)":[29],"<":[30,76,129,156,200],"60)":[31],"or":[32,37],"ECOG":[33],"PS":[34],"of":[35,56,132,141,211,237,250],"2":[36],"greater":[38],"(ECOG2+).":[39],"Methods:":[40],"We":[41],"retrospectively":[42],"identified":[43,68],"mBC":[44,213],"treated":[46],"from":[47],"Jan":[48],"2010":[49],"\u2013":[50],"June":[51],"2014":[52],"fromelectronic":[53],"health":[54],"records":[55],"McKesson":[57],"Specialty":[58],"Health/US":[59],"Oncology,":[60],"follow-up":[62],"through":[63],"July":[64],"2016.":[65],"Cis-ineligibility":[66],"was":[67,168,245],"using":[69],"a":[70],"consensus-based":[71],"algorithm":[72],"(pts":[73],"CrCl":[75,155],"60":[77,157],"and/or":[78],"ECOG2+":[79],"classified":[80],"cis-ineligible).":[81],"Results:":[82],"1155":[83],"received":[85,144],"1L":[86,97,149,174,219],"treatment;":[87],"median":[88],"age":[89],"72":[90],"yrs":[91,124],"(range":[92],"26-90+).":[93],"The":[94],"most":[95],"common":[96],"regimens":[98],"were":[99,116,120,222,229,241],"cis/gemcitabine":[100],"(gem)":[101],"(26.8%),":[102],"carboplatin":[103],"(carbo)/gem":[104],"(26.5%),":[105],"carbo/paclitaxel":[106],"(8.9%),":[107],"and":[108,139,158,172,218,227,232],"gem":[109],"alone":[110],"(8.3%).":[111],"Among":[112],"all":[113,251],"pts,":[114,151],"55.2%":[115],"cis-ineligible.":[117],"Cis-ineligible":[118,257],"older":[121],"(mean":[122],"74.4":[123],"vs":[125],"66.5":[126],"yrs;":[127],"p":[128],"0.0001).":[130,201],"48.7%":[131],"eligible":[133],"did":[135],"not":[136],"receive":[137],"cis,":[138,180,185,190,195],"25.4%":[140],"cis-based":[145],"therapy.":[146],"Interestingly,":[147],"among":[148],"cis/gem":[150],"34.5":[152],"%":[153],"had":[154,160],"11.5%":[159],"ECOG2+.":[161],"Median":[162],"(95%":[163],"CI)":[164],"overall":[165],"survival":[166],"(OS)":[167],"affected":[169],"by":[170,173],"cis-eligibility":[171,216],"cis":[175,220,244],"receipt":[176,221],"as":[177],"follows:":[178],"eligible/received":[179],"17.6":[181],"mos":[182,187,192,197],"(15.1-23.6);":[183],"eligible/no":[184],"14.6":[186],"(11.5-16.7);":[188],"ineligible/received":[189],"13.4":[191],"(10.6-16.8);":[193],"ineligible/no":[194],"9.5":[196],"(8.2-11.4);":[198],"(p":[199],"Conclusions:":[202],"To":[203],"date,":[204],"this":[205],"the":[207],"largest":[208],"reported":[209],"cohort":[210],"real-world":[212],"pts.":[214],"Both":[215],"classification":[217],"associated":[223],"longer":[225],"OS,":[226],"both":[228],"approximately":[230],"equivalent":[231],"additive":[233],"in":[234,247],"their":[235,255,265],"magnitude":[236],"effect.":[238],"Most":[239],"cis-ineligible;":[242],"nonetheless,":[243],"used":[246],"one":[248],"fourth":[249],"despite":[254],"classification.":[256],"have":[259],"high":[260],"unmet":[261],"medical":[262],"need":[263],"given":[264],"inferior":[266],"survival.":[267]},"counts_by_year":[{"year":2020,"cited_by_count":1}],"updated_date":"2026-09-26T08:19:03.415552","created_date":"2018-09-27T00:00:00"}